title: Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.
abstract: BACKGROUND
  Adequate contraceptive advice is important in both women with diabetes mellitus type 1 and type 2 to reduce the risk of maternal and infant morbidity and mortality in unplanned pregnancies. A wide variety of contraceptives are available for these women. However, hormonal contraceptives might influence carbohydrate and lipid metabolism and increase micro- and macrovascular complications, so caution in selecting a contraceptive method is required.
  
  
  OBJECTIVE
  To investigate whether progestogen-only, combined estrogen and progestogen or non-hormonal contraceptives differ in terms of effectiveness in preventing pregnancy, in their side effects on carbohydrate and lipid metabolism, and in long-term complications such as micro- and macrovascular disease when used in women with diabetes mellitus.
  
  
  METHODS
  The search was performed in CENTRAL, MEDLINE, EMBASE, POPLINE, CINAHL, WorldCat, ECO, ArticleFirst, the Science Citation Index, the British Library Inside, and reference lists of relevant articles. The last search was performed in January 2013. In addition, experts in the field and pharmaceutical companies marketing contraceptives were contacted to identify published, unpublished or ongoing studies.
  
  
  METHODS
  Randomised and quasi-randomised controlled trials that studied women with diabetes mellitus comparing: 1. hormonal versus non-hormonal contraceptives; 2. progestogen-only versus estrogen and progestogen contraceptives; 3. contraceptives containing < 50 µg estrogen versus contraceptives containing ≥ 50 µg estrogen; and 4. contraceptives containing first-, second- and third-generation progestogens, drospirenone and cyproterone acetate. The principal outcomes were contraceptive effectiveness, diabetes control, lipid metabolism and micro- and macrovascular complications.
  
  
  METHODS
  Two investigators evaluated the titles and abstracts identified from the literature search. Quality assessment was performed independently with discrepancies resolved by discussion or consulting a third review author. Because the trials differed in studied contraceptives, participant characteristics and methodological quality, we could not combine the data in a meta-analysis. The trials were therefore examined on an individual basis and narrative summaries were provided.
  
  
  RESULTS
  Four randomised controlled trials were included. No unintended pregnancies were reported during the study periods. Only one trial was of good methodological quality. It compared the influence of a levonorgestrel-releasing intrauterine device (IUD) versus a copper IUD on carbohydrate metabolism in women with type 1 diabetes mellitus. No significant difference was found between the two groups. The other three trials were of limited methodological quality. Two compared progestogen-only pills with different estrogen and progestogen combinations, and one also included the levonorgestrel-releasing IUD and copper IUD. The trials reported that blood glucose levels remained stable during treatment with most regimens. Only high-dose combined oral contraceptives and 30 µg ethinylestradiol + 75 µg gestodene were identified as slightly impairing glucose homeostasis. The three studies found conflicting results regarding lipid metabolism. Some combined oral contraceptives appeared to have a minor adverse effect while others appeared to slightly improve lipid metabolism. The copper IUD and progestogen-only oral contraceptives also slightly improved lipid metabolism and no influence was seen while using the levonorgestel-releasing IUD. Only one study reported on micro- and macrovascular complications. It observed no signs or symptoms of thromboembolic incidents or visual disturbances, however study duration was short. Only minor adverse effects were reported in two studies.
  
  
  CONCLUSIONS
  The four included randomised controlled trials in this systematic review provided insufficient evidence to assess whether progestogen-only and combined contraceptives differ from non-hormonal contraceptives in diabetes control, lipid metabolism and complications. Three of the four studies were of limited methodological quality, sponsored by pharmaceutical companies and described surrogate outcomes. Ideally, an adequately reported, high-quality randomised controlled trial analysing both intermediate outcomes (that is glucose and lipid metabolism) and true clinical endpoints (micro- and macrovascular disease) in users of combined, progestogen-only and non-hormonal contraceptives should be conducted. However, due to the low incidence of micro- and macrovascular disease and accordingly the large sample size and long follow-up period needed to observe differences in risk, a randomised controlled trial might not be the ideal design.
authors.affiliation: Department of Obstetrics and Gynaecology, Leiden University Medical Center, Leiden, Netherlands. jantienvisser@gmail.com.
authors.forename: Jantien
authors.initials: J
authors.lastname: Visser
authors.forename: Marieke
authors.initials: M
authors.lastname: Snel
authors.forename: Huib A A M
authors.initials: HA
authors.lastname: Van Vliet
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage / Q000009:adverse effects; D050356:Lipid Metabolism / Q000187:drug effects; D011247:Pregnancy; D011372:Progestins / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic
chemical_list: D001786:Blood Glucose; D003271:Contraceptive Agents, Female; D003278:Contraceptives, Oral, Hormonal; D011372:Progestins; D016912:Levonorgestrel
references.citation: Am J Obstet Gynecol. 1994 Aug;171(2):400-5
references.pmid: 8059818
references.citation: Gynecol Endocrinol. 2006 Apr;22(4):198-206
references.pmid: 16723306
references.citation: Diabetes Care. 1999 Dec;22(12):1984-7
references.pmid: 10587830
references.citation: Lancet. 2004 May 22;363(9422):1728-31
references.pmid: 15158638
references.citation: Diabetologia. 1989 May;32(5):300-4
references.pmid: 2666216
references.citation: BMJ. 2003 May 31;326(7400):1167-70
references.pmid: 12775614
references.citation: Acta Endocrinol Suppl (Copenh). 1986;277:125-9
references.pmid: 3532663
references.citation: Gynecol Endocrinol. 2010 Sep;26(9):663-8
references.pmid: 20334583
references.citation: Gynecol Endocrinol. 2008 Feb;24(2):99-104
references.pmid: 18210334
references.citation: JAMA. 1994 Apr 13;271(14):1099-102
references.pmid: 8151852
references.citation: Fertil Steril. 1986 Nov;46(5):858-64
references.pmid: 3781003
references.citation: Geburtshilfe Frauenheilkd. 1994 Dec;54(12):691-6
references.pmid: 7851711
references.citation: Diabetologia. 1991 May;34(5):356-61
references.pmid: 1864491
references.citation: Arch Intern Med. 2001 Sep 10;161(16):2000-5
references.pmid: 11525702
references.citation: Arch Intern Med. 1993 Oct 11;153(19):2209-16
references.pmid: 8215724
references.citation: Lancet. 2002 Feb 23;359(9307):696-700
references.pmid: 11879884
references.citation: Obstet Gynecol. 2005 May;105(5 Pt 1):1114-8
references.pmid: 15863552
references.citation: Ugeskr Laeger. 1996 Apr 22;158(17):2388-92
references.pmid: 8685993
references.citation: J Obstet Gynaecol Res. 2000 Feb;26(1):17-26
references.pmid: 10761326
references.citation: N Engl J Med. 1982 Jun 3;306(22):1332-7
references.pmid: 7070458
references.citation: Lancet. 2002 Feb 16;359(9306):614-8
references.pmid: 11867132
references.citation: Drugs. 2000 Oct;60(4):721-869
references.pmid: 11085198
references.citation: JAMA. 1995 Nov 8;274(18):1456-8
references.pmid: 7474192
references.citation: Lancet. 1979 May 19;1(8125):1045-9
references.pmid: 86774
references.citation: Lancet. 2002 Mar 2;359(9308):781-5
references.pmid: 11888606
references.citation: Am J Obstet Gynecol. 1990 Jul;163(1 Pt 2):382-7
references.pmid: 2196809
references.citation: Diabetes Care. 1992 Nov;15(11):1585-90
references.pmid: 1468289
references.citation: J Intern Med Suppl. 1996;738:1-60
references.pmid: 9010389
references.citation: Diabetes Res Clin Pract. 2005 Mar;67(3):267-72
references.pmid: 15713360
references.citation: J Reprod Med. 1986 Sep;31(9 Suppl):892-7
references.pmid: 3095547
references.citation: Horm Metab Res. 1982 Feb;14(2):61-5
references.pmid: 7040192
references.citation: Obstet Gynecol. 2005 Apr;105(4):811-5
references.pmid: 15802410
references.citation: Contraception. 1976 Mar;13(3):299-311
references.pmid: 55331
references.citation: J Clin Endocrinol Metab. 1992 Jan;74(1):64-70
references.pmid: 1530790
references.citation: Diabetes Care. 1995 Jun;18(6):800-6
references.pmid: 7555506
references.citation: Br J Sociol. 2010 Jan;61 Suppl 1:185-219
references.pmid: 20092493
references.citation: N Engl J Med. 1990 Nov 15;323(20):1375-81
references.pmid: 2146499
references.citation: N Y State J Med. 1967 Apr 15;67(8):1073-4
references.pmid: 5232498
references.citation: Diabetes Care. 1999 Feb;22(2):248-52
references.pmid: 10333941
references.citation: Eur J Contracept Reprod Health Care. 2011 Oct;16(5):350-8
references.pmid: 21777049